Eli Lilly & Co. vs Madrigal Pharmaceuticals, Inc.
LLY vs MDGL — side-by-side comparison from reported financials. LLY leads 6, MDGL leads 3 of 9 comparable metrics.
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
Madrigal Pharmaceuticals, Inc.
MDGL · Healthcare
$471.75-1.08%Strong
| Metric | LLY | MDGL |
|---|---|---|
| Price | $1 177.20 | $471.75 |
| Market cap | $1.05T | $10.9B |
| Revenue (TTM) | $79.7B | $1.28B |
| Revenue growth | +31.7% | +149.0% |
| Net margin | 33.5% | -25.3% |
| Free cash flow | $18.2B | -$207M |
| Net cash (debt) | ($35.2B) | $644M |
| 1-year price return | +37.6% | +10.1% |
| P/E | 41.6 | — |
| P/E vs own history (cheap-side %) | 88% | — |
| Dividend yield | 0.52% | — |
| Return on equity | 93% | -57% |
| Altman Z-score | 7.10 | 7.49 |
| CV checks passed | 11 of 11 | 5 of 11 |
| Employees | 50,000 | 915 |
Full résumé-style profiles: LLY CV · MDGL CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.